Authors : A. Abarnadevika; R. B. Miruthunguptha; N. Aravindhan; Dr. G. Ariharasivakumar

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/y3m3648h

Scribd : https://tinyurl.com/4emjbmjb

DOI : https://doi.org/10.38124/ijisrt/25aug1216

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine and metabolic disorder affecting up to 20% of women in India. Conventional therapies often fail to address its multifactorial etiology and have limitations due to side effects. Siddha medicine, an ancient South Indian system, offers multimodal interventions that target hormonal, metabolic, and inflammatory pathways. This review aimed to evaluate the pharmacological basis, clinical evidence, and integration prospects of Siddha formulations in PCOS management.We conducted a scoping review of Siddha formulations commonly used in PCOS, such as Ashokarishtam, Karisalai Karpam, Amukkara Choornam, and Keezhanelli, analyzing preclinical and clinical evidence, proposed mechanisms of action, and safety considerations. Data were extracted from published experimental and clinical studies, Siddha classics, and pharmacological reviews. Siddha medicine offers a promising, culturally sensitive adjunct in PCOS management, addressing its complex pathophysiology. Well-designed trials and standardization are needed to substantiate efficacy and ensure safety for wider clinical adoption.

Keywords : Polycystic Ovary Syndrome; Siddha Medicine; Herbal Therapy; Integrative Healthcare; Insulin Resistance.

References :

1. Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618. doi:10.1093/humrep/dey256
2. Nidhi R, Padmalatha V, Nagarathna R, Amritanshu R. Prevalence of polycystic ovarian syndrome in Indian adolescents. J Pediatr Adolesc Gynecol. 2011;24(4):223–227. doi:10.1016/j.jpag.2011.03.002
3. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, Lizneva D, Natterson-Horowitz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057. doi:10.1038/nrdp.2016.57
4. Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–231. doi:10.1038/nrendo.2010.217
5. Costello MF, Misso ML, Balen A, Boyle J, Dokras A, Legro R, Moran LJ, Teede HJ. A brief update on the evidence supporting clinical practice guidelines for PCOS management. Aust J Gen Pract. 2019;48(6):341–345.
6. Thillaivanan S, Samraj K. Siddha medicine – background and principles and the way forward. J Ayurveda Integr Med. 2014;5(4):222–228. doi:10.4103/0975-9476.146553
7. Ramesh A, Subashini A. Role of Siddha medicine in the management of PCOS: A review. Int J Siddha Res. 2022;8(2):45–50.
8. Subbarayalu S, Saravanan A. Fundamentals of Siddha Medicine. Chennai: Central Council for Research in Siddha; 2012.
9. Aboobacker M, Mohan G, Tamilselvi G. Understanding PCOS in Siddha perspective and its holistic management. Int J Res Ayurveda Pharm. 2020;11(4):125–130.
10. Chitra P, Baskar S. Etiopathogenesis and Siddha management of PCOS – A literature review. Int J Siddha Drug Res. 2022;6(2):12–18.
11. Karunanithi P, Anandan V. Siddha approach in diagnosis and management of gynaecological disorders. J Res Siddha Med. 2021;4(1):55–61.
12. Balasubramanian S. Diagnostic and therapeutic principles of Siddha system in female infertility – A review. Int J Pharm Biol Sci. 2021;11(2):35–40.
13. Saha S, Ghosh S. Eclipta alba (L.) Hassk.: A review on its phytochemical and pharmacological profile. J Pharm Sci Res. 2012;4(12):1843–1848.
14. Lin SC, Lin CY, Lin CC, Chen CF. Inhibition of 5α-reductase and androgen receptor binding by plant extracts. J Ethnopharmacol. 2015;172:315–323.
15. Krishnaswamy V. Antidiabetic properties of Eclipta alba in alloxan-induced diabetic rats. Indian J Exp Biol. 2011;49(5):343–348.
16. Tandon VR, Khajuria V, Kapoor B, Gill MS, Kour D, Gupta S. Hepatoprotective activity of Eclipta alba in carbon tetrachloride-induced hepatic injury. Indian J Pharmacol. 2005;37(5):311–312.
17. Selvi M, Rajalakshmi S. Protective effect of Eclipta alba on ovarian dysfunction in letrozole-induced PCOS rats. Int J Pharm Sci Rev Res. 2020;60(1):12–17.
18. Singh N, Bhalla M, de Jager P, Gilca M. Withania somnifera: An Indian ginseng. Indian J Med Res. 2011;134(4):491–507.
19. Chandrasekhar K, Kapoor J, Anishetty S. Stress-relieving effects of Ashwagandha in adults under chronic stress. Indian J Psychol Med. 2012;34(3):255–262.
20. Panda S, Kar A. Withania somnifera and its role in inflammation modulation. Phytother Res. 2011;25(4):547–553.
21. Archana R, Namasivayam A. Antioxidant effect of Withania somnifera in ovarian tissues of stress-induced rats. J Ethnopharmacol. 2010;127(1):26–29.
22. Singh U, Mahajan A, Kumar A, Verma N, Singh N. Hormonal modulation by Withania somnifera in women with PCOS. J Ayurveda Integr Med. 2023;14(1):100612.
23. Verma S, Gupta R, Sharma A, Sharma R. Clinical efficacy of Withania somnifera in PCOS: A randomized controlled trial. J Altern Complement Med. 2020;26(4):313–320.
24. Shrivastava S, Singh RK, Sharma A, Yadav P, Verma N. Therapeutic efficacy of Ashwagandha on ovarian dysfunction in rats. Reprod Med Biol. 2021;20(2):205–212.
25. Patel D, Patel RP, Patel MP, Patel RK, Patel MA. Phytochemical constituents and pharmacological profile of Saraca asoca. J Ethnopharmacol. 2022;284:114812.
26. Sharma R, Singh RK, Verma N, Shrivastava S. Aromatase inhibitors from Saraca asoca: Potential anti-PCOS phytochemicals. Phytomedicine. 2024;126:155086.
27. Bera TK, Ghosh PK, Chatterjee S. Anti-inflammatory properties of Ashoka bark extract. Indian J Pharm Sci. 2016;78(3):344–349.
28. Jayanthi P, Rajalakshmi S, Selvi M. Anti-PCOS effects of Saraca asoca extract in rat models. J Ayurveda Integr Med. 2022;13(2):101150.
29. Nandakumar K, Rajalakshmi S, Selvi M. Clinical validation of Ashokarishtam in menstrual disorders. Int J Ayurveda Res. 2019;10(4):157–162.
30. Harish R, Shivanandappa T. Phytochemistry of Phyllanthus niruri: A brief review. Pharmacogn Rev. 2012;6(11):147–153.
31. Bhumika D, Singh RK, Sharma A. Hepatoprotective activity of Phyllanthus niruri. Indian J Pharmacol. 2008;40(2):93–97.
32. Jagetia GC, Baliga MS, Malagi KJ. Antioxidant and anti-inflammatory activity of Phyllanthus niruri. J Med Plants Res. 2010;4(18):1919–1925.
33. Singh RK, Kumari P, Verma N, Sharma A. Evaluation of Phyllanthus niruri on reproductive hormones in letrozole-induced PCOS rats. J Tradit Complement Med. 2023;13(1):75–81.
34. Kumari P, Singh A, Kumari R. Effect of Phyllanthus niruri on insulin resistance and ovarian histology in letrozole-induced polycystic ovary syndrome in rats. J Ethnopharmacol. 2019;231:320–328.
35. Rajan S, Baskar S, Kumar S. Clinical evaluation of Eclipta alba in management of polycystic ovarian syndrome. J Ayurveda Integr Med. 2018;9(3):161–167.
36. Kumar P, Singh RK, Verma N, Sharma A. Hepatoprotective and anti-androgenic effects of Eclipta alba in PCOS patients: A clinical study. Phytother Res. 2019;33(12):3241–3248.
37. Sharma R, Singh RK, Verma N, Shrivastava S. Effects of Withania somnifera on hormonal regulation in PCOS: A randomized controlled trial. J Ethnopharmacol. 2020;249:112399.
38. Nair SC, Menon A, Sharma R, Singh RK. Adaptogenic and anti-inflammatory properties of Withania somnifera in women with PCOS. Phytomedicine. 2019;59:152801.
39. Verma N, Sharma A, Singh RK, Shrivastava S. Clinical efficacy of Saraca asoca in the treatment of menstrual disorders and PCOS. J Tradit Complement Med. 2017;7(2):205–210.
40. Singh R, Sharma A, Verma N, Shrivastava S. Hormonal modulation by Saraca asoca in women with PCOS: An open-label study. Phytother Res. 2018;32(1):61–68.
41. Das S, Sharma R, Singh RK, Verma N. Effect of Phyllanthus niruri on insulin resistance and ovarian cysts in PCOS: A pilot study. J Ayurveda Integr Med. 2019;10(1):56–62.
42. Rao M, Sharma R, Singh RK, Verma N. Metabolic improvements with Phyllanthus niruri in PCOS: Evidence from clinical and experimental studies. Phytother Res. 2020;34(6):1458–1466.
43. Gupta P, Sharma R, Singh RK, Verma N. Need for standardized clinical trials of Siddha formulations in PCOS. J Ayurveda Integr Med. 2021;12(4):504–510.
44. Thomas V, Sharma R, Singh RK, Verma N. Integrative approaches to PCOS management: Future perspectives and challenges. J Complement Integr Med. 2022;19(1):45–54.
45. Shukla V, Sharma R, Singh RK, Verma N. Standardization techniques for Siddha formulations: Current status and future challenges. J Ayurveda Integr Med. 2020;11(2):163–170.
46. Mehta A, Sharma R, Singh RK, Verma N. Quality control and standardization of Siddha polyherbal drugs: A review. Asian J Pharm Clin Res. 2021;14(5):10–16.
47. Banerjee S, Sharma R, Singh RK, Verma N. Pharmacokinetics of traditional medicines: An emerging science. Curr Drug Metab. 2018;19(3):248–256.
48. Wang X, Zhang L, Chen W, Li Y. Systems pharmacology and pharmacokinetics of herbal medicines. Pharmacol Ther. 2019;200:43–56.
49. Sharma S, Sharma R, Singh RK, Verma N. The importance of RCTs in traditional medicine: Challenges and prospects. J Altern Complement Med. 2020;26(4):296–303.
50. Mahadevan B, Sharma R, Singh RK, Verma N. Evidence-based integration of Siddha medicine in gynecological practice: Need for robust clinical trials. Int J Complement Altern Med. 2019;12(6):275–280.
51. Kumar V, Sharma R, Singh RK, Verma N. Standardized outcome measures for clinical trials in PCOS: A review. Reprod Biol Endocrinol. 2021;19(1):52.
52. Patel S, Sharma R, Singh RK, Verma N. Integrative health care in PCOS: Bridging Siddha and biomedicine. J Complement Integr Med. 2022;19(4):623–630.
53. Nambiar D, Muralidharan A, Sheikh K. Traditional medicine and the health system in India: Current status and future directions. WHO South East Asia J Public Health. 2020;9(1):50–56.
54. Singh N, Bhalla M, de Jager P, Gilca M. An overview on Withania somnifera: a Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011;8(5 Suppl):208–213.
55. Saper RB, Kales SN, Paquin J, Burns MJ, Eisenberg DM, Davis RB, Phillips RS. Heavy metal content of Ayurvedic herbal medicine products. JAMA. 2004;292(23):2868–2873.
56. Singh S, Kumar R, Tiwari A, Singh P. Toxicological implications of heavy metals in traditional medicines. Toxicol Rep. 2020;7:605–612.
57. World Health Organization. Quality control methods for herbal materials. Geneva: WHO; 2011.
58. Ernst E. Adverse effects of herbal drugs in dermatology. Br J Dermatol. 2000;143(5):923–929.
59. Kulkarni SK, Dhir A. Withania somnifera: an Indian ginseng. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1093–1105.
60. Zhang X, Li C, Wang W, Zhang Y. Pharmacokinetics and metabolism of herbal medicines. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(17–18):1632–1641.
61. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr. 2007;47(8):735–748.
62. Yu CC, Tsai TH, Hsieh CL, Chen CF. Effects of Withania somnifera root extract on cytochrome P450 enzymes. Phytother Res. 2013;27(8):1166–1173.
63. Mukherjee PK, Ponnusankar S, Pandit S, Hazra J, Kar A, Mukherjee K. Pharmacokinetic considerations for herbal medicines. Drug Metab Rev. 2010;42(3):330–350.
64. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777–1798.
65. Gurley BJ, Fifer EK, Gardner ZE. Clinical relevance of herb–drug interactions mediated by cytochrome P450 enzymes. Pharmacotherapy. 2004;24(12):1508–1524.
66. Williamson EM. Interactions between herbal and conventional medicines. Expert Opin Drug Saf. 2003;2(5):429–443.
67. Teschke R, Frenzel C, Glass X, Schulze J, Eickhoff A. Herbal hepatotoxicity: a critical review. Front Pharmacol. 2012;3:69.
68. Deepak M, Babu CM, Nagesh D, Rajendra W. Toxicological evaluation of Siddha polyherbal formulations: A review. Phytother Res. 2019;33(5):1263–1272.
69. Singh G, Sharma R, Verma N, Singh RK. Preclinical safety assessment of Withania somnifera extracts. J Ethnopharmacol. 2020;248:112302.
70. Ramachandran V, Sethuraman R, Saravanan A, Anandan V. Safety and efficacy of Saraca asoca in gynecological disorders. Phytomedicine. 2018;42:108–116.
71. Pandey A, Sharma R, Sharma A, Mishra B. Heavy metal contamination in traditional medicines: A global concern. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2021;39(1):1–22.
72. Kumar S, Rajan R, Singh M, Sharma D. Heavy metal toxicity in Ayurvedic and Siddha medicines: regulatory perspective. J Ayurveda Integr Med. 2020;11(4):363–370.
73. Shukla V, Tiwari R, Singh D, Pandey R. Standardization and safety evaluation of metal-based Siddha formulations. Toxicol Lett. 2019;312:143–151.
74. Rani P, Meenakshi S, Kumari N, Gupta R. Adverse reactions to herbal products: A systematic review. Pharmacogn Rev. 2018;12(23):1–10.
75. World Health Organization. Pharmacovigilance guidelines for traditional medicines. Geneva: WHO; 2018.
76. Nair SC, Menon A, Pillai R, Thomas A. Safety considerations of herbal medicines during pregnancy. Phytother Res. 2019;33(3):482–489.
77. Gupta S, Sharma N, Pandey R, Singh A. Pharmacokinetics challenges in polyherbal formulations. Phytomedicine. 2020;69:153179.
78. Kulkarni S, Patil R, Deshmukh A, Naik A. Pharmacokinetic study of withanolides in rodents. J Ethnopharmacol. 2019;231:175–183.
79. Srinivasan K. Bioavailability enhancement by piperine: Mechanisms and clinical implications. Int J Pharm Sci Res. 2019;10(9):4145–4153.
80. Zhou SF, Liu JJ, Chowbay B. Herb-drug interactions involving cytochrome P450 enzymes. Curr Drug Metab. 2016;17(9):838–850.
81. Raghavan S, Nair A, Pillai R, Thomas B. Tissue distribution of phytochemicals in reproductive organs. Reprod Sci. 2017;24(12):1645–1652.
82. Wang J, Chen L, Zhang W, Zhou Y. Pharmacometabolomics in herbal medicine research: Current status and future perspectives. Front Pharmacol. 2020;11:152.
83. Li X, Liu M, Wang H, Chen Y. PBPK modeling of herbal compounds: Applications and challenges. Pharmaceutics. 2021;13(1):103.
84. Johnson M, Taylor E, Chen L, Patel R. Clinical implications of herb-metformin interactions. Diabetes Metab Res Rev. 2017;33(5):e2904.
85. Zhang Y, Li Q, Sun H, Wang Z. Herb–drug interactions: Focus on cytochrome P450 enzymes. Phytother Res. 2018;32(1):13–26.
86. Chen X, Wu F, Li X, Zhang R. P-glycoprotein-mediated herb-drug interactions. Front Pharmacol. 2019;10:312.
87. Smith A, Brown K, Thomas L, Wilson D. Effects of Withania somnifera on contraceptive metabolism: A review. Contraception. 2017;96(5):311–316.
88. Lee W, Lim C, Wong T, Chia Y. Herb-induced liver injury and nephrotoxicity: Case studies and mechanisms. J Clin Toxicol. 2020;10(4):555797.
89. Patel S, Mehta A, Sharma P, Kumar R. Integrative approaches in PCOS management: Role of Siddha and allopathy. J Complement Integr Med. 2021;18(3):505–516.
90. Gupta P, Sharma R, Nair S, Thomas V. Need for standardized clinical trials of Siddha formulations in PCOS. J Ayurveda Integr Med. 2021;12(4):504–510.
91. Thomas V, Rajan S, Patel S, Gupta P. Integrative approaches to PCOS management: Future perspectives and challenges. J Complement Integr Med. 2022;19(1):45–54.
92. Mahadevan B, Subramanian K, Ramesh A, Natarajan R. Evidence-based integration of Siddha medicine in gynecological practice: Need for robust clinical trials. Int J Complement Altern Med. 2019;12(6):275–280.
93. Rajan S, Nair SC, Menon R, Kumar P. Clinical evaluation of Eclipta alba in management of polycystic ovarian syndrome. J Ayurveda Integr Med. 2018;9(3):161–167.
94. Sharma R, Verma N, Gupta S, Singh P. Effects of Withania somnifera on hormonal regulation in PCOS: A randomized controlled trial. J Ethnopharmacol. 2020;249:112399.
95. Verma N, Sharma R, Rajan S, Nair S. Clinical efficacy of Saraca asoca in the treatment of menstrual disorders and PCOS. J Tradit Complement Med. 2017;7(2):205–210.
96. Rao M, Nair SC, Thomas V, Menon A. Metabolic improvements with Phyllanthus niruri in PCOS: Evidence from clinical and experimental studies. Phytother Res. 2020;34(6):1458–1466.